Conditional VHL Gene Deletion Causes Hypoglycemic Death Associated with Disproportionately Increased Glucose Uptake by Hepatocytes through an Upregulated IGF-I Receptor

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Kurabayashi, Atsushi ^a   Kakinuma, Yoshihiko ^a   Morita, Taku ^b   Inoue, Keiji ^a   Sato, Takayuki ^a   Furihata, Mutsuo ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b Department of Internal Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN RECEPTOR; RECEPTOR FOR ACTIVATED C KINASE 1; SOMATOMEDIN C RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEATH; DOWN REGULATION; GENE; GENE DELETION; GENE INACTIVATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOGLYCEMIA; LIVER; LIVER CELL; LIVER PRESERVATION; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; UPREGULATION; VHL GENE;

ANIMALS; CAUSE OF DEATH; CELL LINE; GENE DELETION; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HEPATOCYTES; HUMANS; HYPOGLYCEMIA; INSULIN-SECRETING CELLS; LIVER; MICE; MICE, KNOCKOUT; NEUROPEPTIDES; NITRIC OXIDE SYNTHASE TYPE III; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

MUS;

EID: 84879943224     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069139     Document Type: Article

References (31)

1. Latif F, Tory K, Gnarra J, Yao M, Duh FM, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Sience 260: 1317-1320.
2. Richard D, Berra E, Pouyssegur J, (2000) Nonhypoxic pathway mediates the induction of hypoxia-inducible factor-1 alpha in vascular smooth muscle cells. J Biol Chem 275: 26765-26771.
3. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
4. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, et al. (2002) Structure of an HIF-1α-pVHL complex: hydroxyproline recognition in signaling. Science 296: 1886-1889.
5. Iguchi M, Kakinuma Y, Kurabayashi A, Sato T, Shuin T, et al. (2008) Acute inactivation of the VHL gene contributes to protective effect of ischemic preconditioning in the mouse kidney. Nephron Exp Nephrol 110: e82-e90.
6. Morita T, Kakinuma Y, Kurabayashi A, Fujieda M, Sato T, et al. (2011) Conditional VHL gene deletion activates a local NO-VEGF axis in a balanced manner reinforcing resistance to endothelium-targeted glomerulonephropathy. Nephrol Dial Transplant 26: 4023-4031.
7. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, et al. (1997) Nitric oxide system lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 99: 2625-2634.
8. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, et al. (2001) Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 104: 342-345.
9. Feldman EL, Sullivan KA, Kim B, Russell JW, (1997) Insulin-like growth factors regulate neuronal differentiation and survival. Neurobiol Dis 4: 201-214.
10. Ron D, Jiang Z, Yao L, Vagts A, Diamond I, et al. (1999) Coordinated movement of RACK1 with activated βIIPKC. J Biol Chem 274: 27039-27046.
11. Sepp-Lorenzino L, (1998) Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat 47: 235-253.
12. Stewart CE, Rotwein P, (1996) Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 76: 1005-1026.
13. Ullrich A, Schlessinger J, (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212.
14. Steele-Perkins G, Turner J, Edman JC, Hari J, Pierce SB, et al. (1988) Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem 263: 11486-11492.
15. Werner H, Woloschak M, Stannard B, Shen-Orr Z, Roberts CT, et al. (1991) The insulin-like growth factor I receptor: Molecular biology, heterogeneity and regulation. In: Insulin-like growth factors: Molecular and cellular aspects. Boca Raton: C.R.C. Press. 17-48p.
16. Entingh-Pearsall A, Kahn CR, (2004) Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I. J Biol Chem 279: 38016-38024.
17. Di Cola G, Cool MH, Accili D, (1997) Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J Clin Invest 99: 2538-2544.
18. Mochly-Rosen D, Smith BL, Chen CH, Disatnik MH, Ron D, (1995) Interaction of protein kinase C with RACK1, a receptor for activated C-kinase: a role in beta protein kinase C mediated signal transduction. Biochem Soc Trans 23: 596-600.
19. McCahill A, Warwicker J, Bolger GB, Houslay MD, Yarwood SJ, (2002) The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. Mol Pharmacol 62: 1261-1273.
20. He X, Wang J, Messing EM, Wu G, (2011) Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness. Oncogene 30: 535-547.
21. Hermanto U, Zong CS, Li W, Wang LH, (2002) RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol Cell Biol 22: 2345-2365.
22. Park SK, Haase VH, Johnson RS, (2007) von Hippel Lindau tumor suppressor regulates hepatic glucose metabolism by controlling expression of glucose transporter 2 and glucose 6-phosphatase. Int J Oncol 30: 341-348.
23. Kucejova B, Sunny NE, Nguyen AD, Hallac R, Fu X, et al. (2011) Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death. Oncogene 30: 2147-2160.
24. Ma W, Tessarollo L, Hong SB, Baba M, Southon E, et al. (2003) Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res 63: 5320-5328.
25. Jadeski LC, Lala PK, (1999) Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 155: 1381-1390.
26. Emile JF, Lemoine A, Azoulay D, Debuire B, Bismuth H, et al. (2001) Histological, genomic and clinical heterogeneity of clear cell hepatocellular carcinoma. Histopathology 38: 225-231.
27. Puri S, Cano DA, Hebrok M, (2009) A role for von Hippel-Lindau protein in pancreatic beta-cell function. Diabetes 58: 433-441.
28. Cantley J, Selman C, Shukla D, Abramov AY, Forstreuter F, et al. (2009) Deletion of the von Hippel-Lindau gene in pancreatic beta cells impairs glucose homeostasis in mice. J Clin Invest 119: 125-135.
29. Yuen JS, Cockman ME, Sullivan M, Protheroe A, Turner GD, et al. (2007) The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 26: 6499-6508.
30. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, et al. (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277: 38205-38211.
31. Chavez JC, LaManna JC, (2002) Activation of hypoxia-inducible factor-1 in the rat cerebral cortex after transient global ischemia: potential role of insulin-like growth factor-1. J Neurosci 22: 8922-8931.